GenScript ProBio logo

GenScript ProBio(1548 (HKEX))

Challenger

GenScript ProBio is the CDMO subsidiary of GenScript Biotech, offering gene synthesis, biologics development, cell therapy manufacturing (CAR-T), and life science CRO services; publicly listed on the Hong Kong Stock Exchange (HK: 1548);

Best for: Biologics CDMO & Cell and Gene Therapy Services
Life Sciences & BioTechBiologics CDMO & Cell and Gene Therapy Services1548 (HKEX)WebsiteUpdated May 2026

Company Overview

About GenScript ProBio

GenScript ProBio is the contract development and manufacturing organization (CDMO) business unit of GenScript Biotech Corporation, one of the world's largest life science research and manufacturing companies. GenScript ProBio provides end-to-end biologics and cell and gene therapy development services, leveraging GenScript's foundational strength in gene synthesis — the company's proprietary gene synthesis technology is the backbone of its CDMO offering and enables highly accurate, rapid construction of complex genetic sequences for therapeutic applications. Services span plasmid and viral vector manufacturing, CAR-T and other cell therapy production, monoclonal antibody development, and comprehensive CRO services for early-stage drug discovery.

Business Model & Competitive Advantage

GenScript Biotech is publicly traded on the Hong Kong Stock Exchange (ticker: 1548.HK), giving ProBio access to public capital markets while operating as a dedicated business unit within the parent's integrated platform. The company's CDMO operations span GMP-compliant manufacturing facilities in the United States, the Netherlands, Singapore, and mainland China — a multi-continental footprint that enables it to serve biopharmaceutical clients across all major regulatory jurisdictions. This global manufacturing capability is a key competitive differentiator as clients seek CDMOs with redundancy and the ability to supply clinical and commercial product across geographies.

Competitive Landscape 2025–2026

GenScript ProBio competes in the fast-growing biologics and cell and gene therapy CDMO market against companies such as Lonza, Samsung Biologics, WuXi Biologics, and Catalent. Its integrated gene synthesis foundation — which means GenScript ProBio can manufacture the genetic starting material as well as the downstream biologic product — provides a vertical integration advantage that pure-play CDMOs cannot easily replicate. The company is positioned to benefit from the continued growth in CAR-T therapies, mRNA platforms, and next-generation biologics as the biopharmaceutical industry increasingly outsources manufacturing to specialized CDMOs.

Curated content • Fact-checked and verified

Key Differentiators

Strong Challenger

GenScript ProBio is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.

Frequently Asked Questions

Similar Brands

BioNTech logo

BioNTech

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingPlatform

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere

Genentech logo

Genentech

Life Sciences & BioTech
B2bGlobalEnterprisePublicHealthtechManufacturingFortune500

Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching

Illumina logo

Illumina

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechAnalyticsHardwarePlatformFortune500

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat

Regeneron logo

Regeneron

Life Sciences & BioTech
B2bGlobalPublicEnterpriseHealthtechManufacturingFortune500

Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m

Neuralink logo

Neuralink

Life Sciences & BioTech
HealthtechHardwareAi PoweredB2b2cStartupDecacornNorth AmericaTechnologyPlatformEnterprise

Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa

Pliant Therapeutics logo

Pliant Therapeutics

BioTech
HealthtechTechnologyPublicB2bStartup

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero

Compare GenScript ProBio with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For GenScript ProBio

Claim This Profile

Are you from GenScript ProBio? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim GenScript ProBio Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention GenScript ProBio vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →